We appreciate the interest in our publication from Dr. Liao who explained why serum HBV DNA has higher frequency of rtM204I/V mutation than serum HBV RNA in chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogs (NAs). Our study demonstrated that the emergence of serum HBV RNA rtM204I/V mutation was generally delayed compared to that of serum HBV DNA, and both of them would ultimately become nearly 100% mutant forms under continuous NA therapy.